TIUMBIO CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,770 KRW | +2.73% |
|
-4.38% | -30.71% |
| Sales 2022 | 9.12B 6.58M | Sales 2023 | 4.9B 3.54M | Capitalization | 241B 174M |
|---|---|---|---|---|---|
| Net income 2022 | -29.85B -21.55M | Net income 2023 | -17.91B -12.93M | EV / Sales 2022 | 31.9 x |
| Net cash position 2022 | 11.89B 8.58M | Net cash position 2023 | 678M 490K | EV / Sales 2023 | 49 x |
| P/E ratio 2022 |
-10.1
x | P/E ratio 2023 |
-13.3
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 58.13% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.73% | ||
| 1 week | -4.38% | ||
| 1 month | -8.14% | ||
| 3 months | -16.11% | ||
| 6 months | -1.60% | ||
| Current year | -30.71% |
1 week
6 410.00
7 100.00
1 month
6 410.008 400.00
Current year
6 400.0010 240.00
1 year
6 290.0011 340.00
3 years
6 290.0027 500.00
5 years
5 800.0029 650.00
10 years
5 800.0029 650.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hoon-Taek Kim
CEO | Chief Executive Officer | 58 | - |
Hyun-Sil Go
DFI | Director of Finance/CFO | 45 | - |
In-Young Song
BRD | Director/Board Member | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mahn-Soon Hwang
BRD | Director/Board Member | 54 | - |
Hoon-Taek Kim
CEO | Chief Executive Officer | 58 | - |
In-Young Song
BRD | Director/Board Member | 51 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 6,770 | +2.73% | 87,562 |
| 24-05-30 | 6,590 | -3.09% | 107,194 |
| 24-05-29 | 6,800 | -1.16% | 26,996 |
| 24-05-28 | 6,880 | -0.15% | 67,702 |
| 24-05-27 | 6,890 | -2.68% | 104,508 |
End-of-day quote Korea S.E., May 30, 2024
More quotes
TiumBio Co., Ltd. is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company researches and develops small molecule drugs including endometriosis treatments, uterine fibroids treatments, cancer immunotherapy drugs; and new biopharmaceuticals including hemophilia treatments, and others.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -30.71% | 127M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- A321550 Stock
